In a bid to improve treatment outcomes, researchers are increasingly investigating ways to tailor radiotherapy to individual tumour biology. In new work, a US centre has used PET hypoxia imaging to identify head-and-neck cancer patients with normoxic, radio-responsive disease and reduce the dose they receive.
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York carried out the pilot study in 33 chemoradiotherapy patients with human papilloma virus positive (HPV+) oropharyngeal cancer. The study is part of a larger trial assessing PET hypoxia imaging in head-and-neck patients. Read more.